-
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
09 Apr 2024 13:20 GMT
… chief commercial officer, Biocon Biologics
Permission granted by Biocon Biologics
Now, … an interchangeable biosimilar — the insulin glargine injection Semglee, a biosimilar … Erick
Chief commercial officer, Biocon Biologics
Erick sees progress being …
-
Biocon obtains approval for diabetes drug Liraglutide in UK
28 Mar 2024 18:16 GMT
… , and the first interchangeable biosimilar Insulin Glargine, approved by the U … Zentiva, commented, “The partnership with Biocon on Liraglutide reaffirms the strong … .
Read also: Eris Lifesciences acquires Biocon Biologics India branded formulation business …
-
Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.
28 Mar 2024 09:47 GMT
… Officer and Managing Director, Biocon Ltd, said: … the first interchangeable biosimilar Insulin Glargine, approved by the … "The partnership with Biocon on Liraglutide reaffirms the … : Equity Bulls
Keywords
Biocon
INE376G01013
UK
MHRA
Approval
…
-
Biocon becomes the first generics company to get a diabetes drug approval in the UK
28 Mar 2024 07:11 GMT
Biocon Ltd. has received approval from … insulin, causing blood sugar levels to be abnormally high.
Siddharth Mittal, Biocon … Shreehas Tambe said.
Shares of Biocon ended little changed on Wednesday …
-
Type 1 Diabetes Market Will Generate Booming Growth Opportunities to 2031: Biocon Ltd., Novo Nordisk, Wockhardt Ltd.
28 Mar 2024 06:49 GMT
… in Market Report are: -
◘ Biocon Ltd.
◘ Novo Nordisk
◘ Gan …
Insulin Syringe
Insulin Pump
Insulin Jet Injectors
By Insulin Type:
Long-Acting Insulin
Rapid-Acting Insulin …
-
Global Insulin Glargine Market Size is projected to reach USD 2200 million by 2031, growing at a CAGR of 6.11%: Straits Research
20 Mar 2024 14:50 GMT
… for the global insulin glargine market. For instance, Biocon Biologics India Ltd … global insulin glargine market players are Novo Nordisk AS, Sanofi Aventis, Biocon … , and technological advancements in insulin delivery devices are opportunities for …
-
Eris Lifesciences Completes Acquisition of Biocon Biologics India Branded Formulation Business
15 Mar 2024 18:40 GMT
… a definitive agreement to purchase Biocon Biologics India-branded formulation division … Chief Operating Officer, the acquired Biocon Biologics domestic formulations business generated … assets gained are two prominent insulin brands – Basalog and Insugen, …
-
Biocon Biologics CEO terms Eris Lifesciences deal as enabling, not restricting
15 Mar 2024 13:22 GMT
Biocon Biologics’ collaboration with Eris … , MD and CEO of Biocon Biologics in an interview with … Insugen are insulin products used in the treatment of diabetes.
Biocon Biologics … one in five insulin-dependent diabetics in the country.
Biocon Biologics will …
-
Eris Lifesciences acquires Biocon Biologics India branded formulation business for Rs 1242 crore
15 Mar 2024 10:11 GMT
… announced the acquisition of Biocon Biologics' India … market in India and Insulins segment.
The acquisition brings … two major insulin brands – Basalog and Insugen … of the acquisition includes Biocon’s Insulin, Critical Care and …
-
Biocon share price slips over 6% after CFO resigns
15 Mar 2024 09:07 GMT
… also announced that its subsidiary Biocon Biologics' India-branded … includes portfolios in insulin, oncology, and critical care. “Biocon Biologics has signed … closing conditions,” the firm said.
Biocon Biologics’ India branded formulation business …